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Summary 
Allergic asthma  is  characterized by airway hyperresponsiveness and pulmonary eosinophilia, 
and may be mediated by T  helper (Th) lymphocytes expressing a Th2 cytokine pattern. Inter- 
leukin  (IL)  12 suppresses  the expression of Th2 cytokines and their associated responses, in- 
cluding eosinophilia, serum immunoglobulin E, and mucosal mastocytosis. We have previously 
shown in a routine model that antigen-induced increases in airway hyperresponsiveness and 
pulmonary eosinophilia are CD4 + T  cell dependent. We used this model to determine the 
ability of IL-12 to prevent antigen-induced increases in airway hyperresponsiveness, broncho- 
alveolar lavage (BAL) eosinophils, and lung Th2 cytokine expression. Sensitized A/J mice de- 
veloped airway hyperresponsiveness and increased numbers of BAL eosinophils and other in- 
flammatory cells  after single  or  repeated intratracheal  challenges with  sheep  red  blood cell 
antigen.  Pulmonary mKNA and protein levels of the Th2 cytokines IL-4 and IL-5 were in- 
creased after antigen challenge. Administration oflL-12 (1  p,g/d ￿  5 d) at the time of a single 
antigen challenge abolished the  airway hyperresponsiveness and pulmonary eosinophilia and 
promoted an increase in interferon (IFN) ~ and decreases in IL-4 and IL-5 expression. The ef- 
fects of IL-12 were partially dependent on IFN-3~, because concurrent treatment with IL-12 
and anti-IFN-~/monoclonal antibody partially reversed the inhibition of airway hyperrespon- 
siveness and eosinophilia by IL-12. Treatment of mice with IL-12 at the time of a second anti- 
gen challenge also prevented airway hyperresponsiveness and significantly reduced numbers of 
BAL inflammatory cells, reflecting the ability of IL-12 to inhibit responses associated with on- 
going antigen-induced pulmonary inflammation. These data show that antigen-induced airway 
hyperresponsiveness and inflammation can be blocked by IL-12, which suppresses  Th2 cyto- 
kine expression. Local administration of IL-12 may provide a novel immunotherapy for the 
treatment of pulmonary allergic disorders such as atopic asthma. 
A~ 
aY hyperresponsiveness and chronic airway inflam- 
ation are fundamental traits  of allergic asthma.  The 
inflammatory component of this disease is characterized by 
increased numbers of activated Th lymphocytes, mast cells, 
and  eosinophils  within  the  airway  lumen  and  bronchial 
submucosa (1-4). Recent studies have shown a strong cor- 
relation between the level of activated CD4 + T  cells and 
disease  severity (2, 5-7). Activated CD4 + T  cells release a 
variety of cytokines that have been proposed to contribute 
to inflammation and airway hyperresponsiveness. The types 
of cytokines released by activated CD4 + T  cells from aller- 
gic asthmatic individuals appear to fit one of the two basic 
patterns  of cytokine  expression  described  in  human  and 
murine CD4 + Th cell clones. Thl  cells  are characterized 
by elevated secretion of IL-2 and IFN-~/, whereas the Th2 
subset ofCD4  + T cells preferentially secrete IL-4, IL-5, IL-6, 
IL-9, and IL-10 (8-10). Examination ofbronchoalveolar la- 
vage (BAL) 1 fluid cells and supematants from allergic asth- 
matics has revealed the existence of Th2-1ike cytokine pat- 
terns (11,  12).  The relative proportions of cells expressing 
Th2  cytokines in  BAL fluid  or biopsies  are  increased in 
symptomatic compared with asymptomatic asthmatic indi- 
viduals (13) and in allergic asthmatic patients after segmen- 
tal allergen challenge (14,  15), suggesting that Th2 cytokine 
1Abbreviations used in this  paper: BAL,  bronchoalveolar  lavage; HPRT, hy- 
poxanthine-guanine phosphoribosyl  transferase;  RT, reverse  transcription. 
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may contribute to allergic reactions and therefore may play 
an important role in the inflammatory reactions and airway 
hyperresponsiveness observed in allergic asthma. In particu- 
lar,  IL-4 modulates  the growth and differentiation  of mast 
cells and regulates IgE synthesis (16, 17), whereas IL-5 con- 
trols the differentiation, recruitment, and activation of eosi- 
nophils  (18-20).  We  and  others  have  demonstrated  the 
functional significance of CD4 + T  cells  (21,  22)  and  IL-5 
(22) in the recruitment of eosinophils into the murine lung 
after  antigen  challenge  and  in  the  development  of airway 
hyperresponsiveness  (21),  suggesting that CD4 + T  cell cy- 
tokine  production  may  play  an  important  role  in  the 
pathogenesis  of allergic  asthma.  Therefore,  an  effective 
therapy for allergic airway reactions may be to prevent the 
development of the Th2 cytokine pattern. 
IL-12 is a recently characterized heterodimeric  cytokine 
(23, 24) that is primarily produced by monocytes and mac- 
rophages (25) in response to infections. IL-12 induces cell- 
mediated  immune  functions,  upregulates  Thl  cytokines, 
especially IFN-y (for review, see reference 26), and inhibits 
or downregulates Th2 cytokines. IL-12 inhibits the devel- 
opment  of IL-4-producing Th2  cells  in response  to anti- 
gens  such  as  Dermatophagoides  pteronyssinus  (27)  and  Leish- 
mania  major  (28,  29).  In  addition,  IL-12  inhibits  IL-4 
production in bulk cultures of peripheral blood leukocytes 
from allergic patients  (27) and also markedly suppresses IL- 
4-mediated  IgE  production  by  human  PBMC  in  vitro 
(30). In murine models ofirnmune activation (31) and par- 
asite  infection  (32,  33),  administration  of IL-12  in  vivo 
suppresses the expression ofTh2 cytokines and their associ- 
ated responses, including eosinophilia, serum IgE, and mu- 
cosal mastocytosis. These studies suggest that IL-12 may be 
an effective suppressor of allergen-induced airway hyperre- 
sponsiveness and inflammation associated with atopic asthma. 
We have recently demonstrated that the development of 
antigen-induced  airway  hyperresponsiveness  and  pulmo- 
nary eosinophilia in a murine model is CD4 + T  cell depen- 
dent  (21),  suggesting that  a  Th2 pattern  of cytokine pro- 
duction  may be associated with  the  development  of these 
allergic responses.  In this study, we have examined the fol- 
lowing:  (a) whether IL-12 treatment could prevent airway 
hyperresponsiveness induced by a single antigen challenge; 
(b) whether IL-12 inhibits pulmonary cellular inflammation 
induced by such antigen challenge; (c) whether IL-12 treat- 
ment alters the pattern of cytokine expression induced by a 
single antigen challenge; (d) whether the effects of IL-12 in 
this model are dependent on IFN-~/; and (e) whether IL-12 
treatment  could  prevent  airway  hyperresponsiveness  and 
inflammation induced by repeated  antigen  challenge.  Our 
results demonstrate that IL-12 was able to abrogate antigen- 
induced airway hyperresponsiveness and pulmonary eosino- 
philia,  concomitant with  suppression  of Th2  cytokine ex- 
pression,  suggesting that these  cytokines play an important 
role in  the  development  of allergic  airway responses.  Fur- 
thermore,  we  demonstrate  that  IL-12 inhibits  airway hy- 
perresponsiveness  and  eosinophilia  after  repeated  antigen 
challenge, suggesting that IL-12 administration may be use- 
ful therapeutically for the modulation of chronic inflamma- 
tion in allergic disorders. 
Materials and Methods 
Animals.  Male  A/J mice,  6-7-wk old, were  obtained from 
The Jackson Laboratory (Bar Harbor, ME). Mice were housed in 
a laminar flow hood in a vires-free animal facility for the duration 
of the experiments.  The studies reported here conformed to the 
principles  for laboratory animal  research  outlined by the Animal 
Welfare Act and the Department of Health, Education, and Wel- 
fare (National Institutes  of Health)  guidelines  for the experimen- 
tal use of animals. 
Effect of IL-12 Administration on Responses after a Single Antigen 
Challenge.  Mice were sensitized and challenged  with SRBC an- 
tigen as previously described (21). Briefly,  mice were sensitized 
by i.p.  injection of 108 SRBC in 0.5 ml PBS.  2 wk later,  mice 
were  anesthetized  by i.p.  injection with a mixture  of ketamine 
and xylazine  (45 and 8 mg/kg, respectively)  and challenged  in- 
tratracheally  with 6  X  108 SRBC in 0.05  ml PBS. The effect of 
murine  rlL-12 on airway responsiveness,  pulmonary inflamma- 
tion,  and  cytokine  expression  was  compared  in  the  following 
groups of mice: naive  (untreated)  mice, sham (PBS)-  or antigen 
(SR_BC)-sensitized, and -challenged mice treated with IL-12 ve- 
hicle  (0.1%  mouse  serum  in  PBS),  antigen-challenged  mice 
treated with low-dose IL-12 (0.I p.g/d ￿  5 d), and sham- or an- 
tigen-challenged mice treated with high dose IL-12 (1 p.g/d ￿  5 d). 
IL-12 or vehicle (0.2 ml) was injected i.p.  -2, -1, +1, and +2 d 
relative  to  antigen  or PBS  challenge.  On  the  day of challenge 
(day 0),  IL-12 or vehicle was administered  with PBS or antigen 
intratracheally  (total volume =  0.05-0.06 ml). 3 d after challenge, 
airway responsiveness  and  numbers  of BAL inflammatory cells 
were determined,  and lungs were saved for measurement of cy- 
tokine expression. 
Dependence of lL-12 Effects on IFN-'y.  In a  separate  group  of 
mice, the dependence of IL-12 effects on IFN-~/activity was de- 
termined.  Mice  were  sensitized  and  challenged  with  antigen, 
treated with vehicle  or IL-12 (1 I~g/d ￿  5 d) as described  above, 
and also injected i.p. with mAb to murine IFN-3, (XMG-6) or an 
irrelevant  isotype-matched control  mAb  (GLl13;  tgGl).  Anti- 
bodies were administered  -2 and + 1 d relative  to antigen chal- 
lenge (2 mg/0.2 ml PBS per injection). 
Effect of lL-12 Administration on Responses after Repeated Antigen 
Challenges.  To determine  if IL-12 diminishes  airway hyperre- 
sponsiveness  associated with established  antigen-induced pulmo- 
nary inflammation,  sensitized  mice were given two intratracheal 
challenges with SRBC (6 ￿  108 SRBC each) separated  by a 7-d 
period.  Preliminary  experiments  showed  that  antigen-induced 
hyperresponsiveness  and inflammation were  enhanced after  this 
repeated antigen challenge protocol (data not shown). Sham groups 
were sensitized and challenged  with PBS only. IL-12 (1 ~tg/d) or 
serum-PBS vehicle was administered  i.p.  -2,  -1,  +1, and +2 d 
relative  to the second challenge  and intratracheally  on day 0 of 
the  second  challenge.  Airway  responsiveness  to  acetylcholine 
challenge and numbers of BAL leukocytes  were measured  on the 
3rd d after the second challenge. 
Airway Responsiveness Measurements.  Airway responsiveness  to 
i.v. acetylcholine challenge  was measured as previously described 
(21). Briefly,  mice were anesthetized  with halothane,  intubated 
with a 20-gauge tracheal  cannula,  and ventilated  at a rate of 120 
breaths per rain with a constant tidal volume of air (0.2 ml). Air- 
way pressure  was measured with a pressure  transducer via a port 
of the  tracheal  cannula.  Further  anesthesia  and muscle  paralysis 
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and decamethonium bromide (50 and 25 mg/kg, respectively) via 
the vena cava. After establishment of a stable airway pressure re- 
cording,  acetylcholine was  injected  i.v.  (25  Ixg/kg),  and  the 
changes in airway pressure were recorded. Airway responsiveness 
was defined by the time-integrated change in peak airway pres- 
sure (airway pressure-time index; centimeters H20 per s). 
Assessment of Ainvay Inflammation.  After airway responsiveness 
measurements,  lungs were lavaged with five 0.7-ml aliquots of 
HBSS solution without calcium or magnesium. The lavage fluid 
was centrifuged 300 g,  10 rain, resuspended in 1 ml HBSS, and 
counted with a hemacytometer. Slide preparations were stained 
with Diff-Quik (Baxter, McGaw Park, IL), and BAL cell differ- 
ential percentages were  determined based on  light microscopic 
evaluation of t>500 cells/slide. 
Isolation ofRNA.  After airway responsiveness measurements, 
the left lung of each mouse was placed in 1 ml R.NAzol B  (Tel- 
Test, Inc., Friendswood, TX) in a sterile cryovial frozen in liquid 
nitrogen, and stored at -80~  The tissue was homogenized and 
RNA was isolated as described in the R_NAzol B protocol. P,.NA 
was resuspended in sterile 10 mM Tris, 1 mM EDTA buffer, pH 
7.5,  made  with  diethylpyrocarbonate-treated water,  and  stored 
with ethanol at  -70~  P,  NA was subsequently recovered and 
quantitated  spectrophotometrically. The  integrity of individual 
R.NA samples was confirmed by electrophoresing aliquots (0.5-1 
Izg) on a 2% agarose gel containing ethidium bromide and ob- 
serving 28- and 18-s rl~NA bands. 
Reverse Transcription-PCR Detection of mRNA.  The  procedures 
for reverse transcription (R.T) and PCR were previously reported 
(33-35) and are briefly described here. 1 btg of total cellular ILNA 
was  mixed with  avian myeloblastosis virus reverse transcriptase 
(2.5 U), dNTPs (dATP, dCTP, dGTP, and dTTP;  1 rnM each), 
R.Nase inhibitor (1 U), oligo(dT)l  6 (2.5  IxM), MgC12 (5 raM) in 
RT-PCR_ buffer (50  mM KC1,  10 mM Tris-HC1, pH 8.3)  in a 
total volume of 20 Ixl. The mixture was incubated at 42~  for 20 
rain in a  thermocycler (Perkin Elmer-Cetus  Instruments,  Nor- 
walk, CT) for RT, followed by incubation at 99~  for 5 min to 
inactivate the transcriptase. The cDNAs were stored at -20~ 
For PCR, 2 p~l of the cDNA preparation was mixed with dNTPs 
(0.2 mM each), paired primers for IFN-% IL-4, IL-5, or hypox- 
anthine-guanine  phosphoribosyl  transferase  (HPRT;  0.5  ~M 
each primer), MgC12 (1.5 mM), and AmpliTaq polymerase (1 U; 
Perkin Elmer-Cetus Instruments)  in R.T-PCP,. buffer in a total 
volume of 50 p~l. The sequences ofcytokine- and HPR.T-specific 
primer pairs and probes were previously reported (35). After ini- 
tial incubation at 95~  for 3 min, PCR_ was carried out under the 
following conditions: denaturation at 95~  for 1 rain, annealing 
at 54~  for 1 rain, and extension at 72~  for 2 rain. After the last 
PCR cycle, samples were incubated an additional 10 rain at 72~ 
for final extension. The  numbers  of PCR  cycles used for each 
primer pair were as follows: IL-4 (33), IL-5 (32), IFN-~/(30), and 
HPR.T  (23).  In  separate  experiments,  we  confirmed  that  this 
number of PCR. cycles was optimal for producing a linear rela- 
tionship between initial quantity of mouse lung R.NA and final 
PCI< product, as previously described (34). As negative controls, 
aliquots of I<NA samples were subjected to PCR. amplification 
without  the  P,T  step.  The  reaction products were  electropho- 
resed and visualized on 2% agarose gel (1% NuSieve GTG [FMC 
Corp., Rockland, ME] and 1% agarose [Sigma Chemical Co., St. 
Louis, MO]) containing 0.5 Ixg/ml ethidium bromide. 
To  estimate the  relative levels of cytokine gene  expression, 
ethidium bromide-stained gels were photographed with type 55 
film (Polaroid Corp., Cambridge, MA). Negatives were scanned 
and band intensities were digitized with a gel scanner (Molecular 
Dynamics,  Sunnyvale, CA),  and the digital data were  analyzed 
(ImageQuant version 3.2;  Molecular Dynamics). A  one-dimen- 
sional  plot  was  computed  by  averaging  the  horizontal  pixels 
across each band (plot profile option). The integrated band inten- 
sities were taken as the OD of the sample (36). Background den- 
sities of the gel were computed and subtracted from cytokine and 
HPI<T band densities, and the expression of each cytokine was 
calculated relative to the intensity of HPRT in each sample (OD 
ratio). These results were confirmed by comparison with South- 
ern blots,  which  were  hybridized with  fluorescein-conjugated, 
cytokine-specific  probes and developed using a chemiluminescence 
detection system  (Amersham Corp.,  Arlington Heights,  IL),  as 
described previously (34). Chemiluminescent signals on ECL hy- 
perfilm (Amersham Corp.) were quantified using a OneScanner 
(Apple Computer, Inc., Cupertino, CA) using National Institutes 
of Health Image. 
Quantitation of Cytokine Protein Levels in BAL Fluid.  In a sep- 
arate experiment, groups of mice were sensitized and challenged 
with antigen or vehicle and treated with IL-12 or vehicle, as de- 
scribed above in the effects of IL-12 administration on responses 
after a single antigen challenge. The following groups were ex- 
amined: sham challenged +  vehicle treated; sham challenged + 
IL-12  treated  (1  Izg/d  ￿  5  d);  antigen  challenged  +  vehicle 
treated; antigen challenged +  IL-12 treated (0.1 Ixg/d >( 5 d); an- 
tigen challenged +  IL-12 treated (1  I~g/d ￿  5 d). 3 d after chal- 
lenge, mice were lavaged three times with one  1-ml aliquot of 
HBSS. The lavage fluid was centrifuged, and aliquots of the su- 
pernatant were stored without further treatment at -80~  until 
analyzed by ELISA. ELISA for IL-4 and IL-5 were conducted us- 
ing matching antibody pairs obtained from PharMingen (San Di- 
ego, CA) according to the manufacturer's instructions. The fol- 
lowing antibody pairs were used for ELISA detection of IL-4 and 
IL-5, respectively: BVD4-1D11  and BVD6-24G2;  TRFK5  and 
JES1-39D10. IFN-~/protein levels were measured by a commer- 
cially available ELISA kit (Genzyme Corp., Cambridge, MA). OD 
readings of samples were converted to picograms per milliliter us- 
ing values obtained from standard curves generated with varying 
concentrations of recombinant IL-4, IL-5, and IFN-y (2000--5 pg/ 
rnl). The limit of detection in each assay was 5 pg/ml. 
Statistical Analysis.  Differences in  airway responsiveness, in- 
flammatory cell numbers,  and cytokine levels among groups of 
mice were determined using analysis of variance (Statview; Aba- 
cus Concepts, Inc., Berkeley, CA). If differences among groups 
were significant (P <0.05), Fisher's protected least significant dif- 
ference test was used to distinguish between pairs of groups. 
Results 
IL-12 Inhibits Airway Responsiveness and Pulmonary  Inflam- 
mation after a Single Antigen Challenge.  To determine iflL- 
12 could reverse antigen-induced airway hyperresponsive- 
ness and inflammation observed 3 d after a single challenge, 
antigen-challenged mice  were  administered two  different 
doses of IL-12 or vehicle for 5  consecutive days beginning 
2  d  before  challenge  and  ending  the  day before  response 
measurements. As previously reported (21), airway reactiv- 
ity  to  i.v.  acetylcholine  challenge  in  antigen-challenged 
mice was significantly increased compared with that in un- 
treated or sham-challenged control mice  (Fig.  1).  In anti- 
gen-sensitized  and  -challenged  animals,  IL-12  caused  a 
dose-dependent inhibition of antigen-induced airway hy- 
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Figure  1.  Effect  oflL-12 on airway responsiveness to i.v. acetylcholine 
(25 Ixg/kgO in mice 3 d after a single intratracheal challenge with antigen 
or PBS (sham). Values shown are mean and SE of 4-15 mice per group. 
Sham- or antigen-challenged mice were injected with vehicle, 0.1 Ixg IL- 
12, or 1 Ixg IL-12 i.p. for 5 consecutive days beginning 2 d before chal- 
lenge; another  group of mice remained untreated.  *P <0.05 compared 
with all other groups except antigen +  0.1 Ixg IL-12. APTI, airway pres- 
sure-time index. 
perresponsiveness. Treatment of mice with 0.1  p.g/d IL-12 
for  5  d  decreased  mean airway responsiveness, but this ef- 
fect was not statistically significant. A  dose of 1 Ixg/d for 5 d 
completely inhibited the  antigen-induced increases in air- 
way responsiveness.  IL-12  (1  pog/d for  5  d)  tended to  re- 
duce  airway  responsiveness  in  sham-challenged  controls, 
but this effect was not statistically significant. 
Consistent with our previous findings (21),  numbers of 
macrophages,  neutrophils,  lymphocytes,  and  eosinophils 
were  all significantly increased in antigen-challenged mice 
compared  with  untreated  and  sham-challenged  control 
groups (Fig. 2). Treatment with IL-12 at either 0.1 or 1 Ixg/d 
for 5  d  resulted in a significant decrease in neutrophils and 
lymphocytes, whereas  macrophage  numbers were  not sig- 
nificantly affected.  Eosinophils were  virtually ablated with 
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Figure  2.  Effect  oflL-12 on numbers of BAL inflammatory cells re- 
covered from mice 3 d after a single antigen or sham challenge. Values 
shown are mean and SE of 4-15 mice per group. Mice were treated as 
described in Fig. 1. * P <0.05 compared with untreated and sham groups; 
t0.05 compared with all other groups; w  compared with untreated, 
sham, and sham +  I I.tg IL-12 groups. 
either  dose  of IL-12.  The  lack of a  statistically significant 
effect of 0.1  p~g/d IL-12 on airway responsiveness after an- 
tigen challenge might have been caused by incomplete pre- 
vention of eosinophilia in lung tissue, which might not be 
reflected in BAL fluids. To assess this possibility, pulmonary 
leukocytes were isolated after lung perfusion, mincing, and 
enzymatic digestion (21).  Treatment with 0.1  p~g/d  IL-12 
for 5  d  prevented the antigen-induced increases in eosino- 
phils observed in lung tissue  (data not shown).  Therefore, 
unlike the effect of IL-12 on airway responsiveness, a dose- 
dependent effect of IL-12 on airway eosinophilia after anti- 
gen  challenge  was  not  observed.  IL-12  administration  in 
sham-challenged  mice  induced  a  significant  increase  in 
numbers ofBAL macrophages, but no other changes, com- 
pared with untreated or sham-challenged controls. 
IL-I2 Inhibits Antigen-induced Increases in Lung Th2 Cyto- 
kine Expression.  The  profiles of cytokine gene expression 
in lung tissues  were  examined using the  RT-PCR  tech- 
nique  (Fig.  3).  Whereas  lungs from  untreated  and  sham- 
challenged  mice  showed  extremely  low  levels  of  IL-4, 
there were  clearly elevated levels of IL-4  mRNA  expres- 
sion in lungs from all antigen-challenged mice. The results 
were  confirmed  by  measuring protein  cytokine  levels  in 
BAL  supernatants (Fig.  4  A).  Similarly, very low levels of 
IL-5 mRNA  were found in lung tissues from untreated and 
sham-challenged mice,  whereas  antigen challenge resulted 
in readily detectable levels of IL-5  transcripts  (Fig.  3).  An 
increase in IL-5 protein levels in BAL fluid of antigen-chal- 
lenged mice was also detected,  although the overall differ- 
ence among groups was not significant (Fig. 4  B).  In con- 
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Figure 3.  Effect  oflL-12 on IFN-% IL-4, and IL-5 mRNA expression 
in lungs of mice 3 d after a single antigen or sham challenge. Sham- or an- 
tigen-challenged mice were treated with vehicle or IL-12 as described in 
Fig. 1. RNA was extracted from tissues and purified using the RNAzol B 
method, reverse-transcribed into cDNA in the presence of oligo-d(T) as a 
primer, and then subjected to varying cycles of PCR as described in Ma- 
terials and Methods. Ampfification of HPRT was performed as a control 
for the total amount of cDNA used in PCR. PeR-amplified products 
were electrophoresed in 2% agarose gel containing 0.5 p,g/ml ethidium 
bromide.  After subtracting background  absorbance, OD ratios of cyto- 
kines to HPRT-amplified products were  calculated. Results shown are 
mean +  SE of OD ratios for IFN-"/, IL-4, and IL-5 in each experimental 
group (n =  5, 2, 7, 3, and 3, respectively, for the five groups listed in the 
figure). 
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IFN-~ (C) protein levels in BAL supernatants of mice 
3 d after a single antigen or sham challenge. Sham- or 
antigen-challenged  mice were treated with vehicle or IL- 
12 as described in Fig. 1. Protein levels were analyzed 
using ELISAs as described in Materials and Methods. 
After subtracting background absorbance, OD readings 
were converted to picograms  per milliliter by compari- 
son with standard curves. Results shown are mean + 
SE of cytokine protein levels for four to seven mice in 
each group. *P <0.05 compared with all other groups; 
~P <0.05 compared with sham group; w  <0.05 com- 
pared with antigen only group. 
trast,  there  was  no appreciable  increase  in  the  intensity  of 
IFN-~/mRNA expression or BAL protein levels in the an- 
tigen-challenged  lungs,  suggesting that  there  is  a  selective 
induction  of a  Th2-1ike  cytokine profile  in  lungs  of mice 
challenged  with  SRBC  antigen.  Because  IL-12  inhibited 
antigen-induced  airway  hyperresponsiveness  and  pulmo- 
nary  inflammation,  we  examined  whether  this  treatment 
inhibited  some of the  Th2  cytokines considered to be re- 
sponsible  for allergic  reactions.  Treatment  with  IL-12 sig- 
nificantly  increased  IFN-~/  mtLNA  expression  and  BAL 
protein  levels  in sham-challenged  mice  (Figs.  3  and 4  C). 
IFN-'y  mlKNA  expression  and  BAL  protein  levels  were 
also significantly increased in antigen-challenged mice after 
treatment  with  two  different  doses  of  IL-12.  A  dose- 
dependent  increase  in  mlKNA levels  was  found,  whereas 
no such dependence was found with IFN-~/protein levels; 
a >  15-fold increase in protein levels was found with either 
dose of IL-12 compared with mice challenged with antigen 
only. Both doses of IL-12 suppressed IL-4 mlLNA expres- 
sion in antigen-challenged mice to a similar degree, which 
was  significant  but  incomplete  in  comparison with  sham- 
challenged mice (Fig. 3). Protein levels of IL-4 in antigen- 
challenged mice,  however, were completely suppressed by 
both doses of IL-12, compared with sham-challenged mice 
(Fig. 4).  Analogous to its  effect on IL-4, both doses of IL- 
l2  inhibited  IL-5  transcript  expression  in  antigen-chal- 
lenged  mice  to  a  comparable  degree.  The  higher  dose  of 
IL-12 inhibited  IL-5 protein levels to a level similar to that 
in  sham-challenged  controls,  but  the  differences  among 
groups was not significant overall. In general the results ob- 
tained with mlKNA and protein levels were in agreement, 
as both demonstrated antigen-induced increases in Th2 cy- 
tokines, IL-12 inhibition ofTh2 cytokines, and increases in 
the  Thl  cytokine; however,  there  were  some  differences. 
The reasons for these discrepancies may be the result of in- 
herent  differences  in  the  kinetics  of mlLNA and  protein 
production and release,  or they may result from the differ- 
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ences in the kinetics between  the two compartments from 
which these levels were measured. The mP,  NA levels were 
derived from cells in the lung interstitium  and the protein 
levels  from fluids  and/or  cells  in  the  airway  spaces.  Cells 
that have migrated into the alveolar spaces may represent a 
different stage of the inflammatory response than  cells that 
still  remain in the interstitium.  In any case, the use of both 
techniques has produced results that are in firm agreement 
with respect to overall trends. 
The  Effects of IL-12  Are  Partially Dependent  on  IFN-  y. 
Measurement  of cytokine  levels  in  lungs  of antigen-chal- 
lenged mice treated with IL-12 suggested that the effects of 
this cytokine may be mediated through IFN-~/release.  To 
investigate  this  possibility,  groups  of vehicle-  or  IL-12- 
treated  mice  were  treated  concurrently  with  anti-[FN-~ 
mAb  or an  isotype-matched  control  antibody.  Treatment 
with  isotype-matched  control  antibody had  no  significant 
effect on airway hyperresponsiveness in vehicle- or IL-12- 
treated, antigen-challenged mice (Fig. 5). Numbers ofeosi- 
nophils were reduced by ~50% in isotype-treated, antigen- 
challenged mice. Treatment with anti-IFN-~ mAb had no 
significant effect on airway hyperresponsiveness  or pulmo- 
nary  eosinophilia  in  vehicle-treated  antigen-challenged 
mice.  Anti-IFN-~/  mAb  partially  reversed  the  IL-12- 
induced  inhibition  of airway  hyperresponsiveness  in  anti- 
gen-challenged mice.  Airway responsiveness  in this  group 
of mice was slightly but not significantly lower than that of 
mice  only challenged  with  antigen.  The  effects  of IL-12, 
however,  were  only partially  dependent  on  IFN-~/;  treat- 
ment  with  anti-IFN-3~  mAb  did  not  significantly reverse 
the  IL-12-induced  depletion  of eosinophils  in  antigen- 
challenged  mice.  Numbers  of eosinophils  in  this  group, 
though not completely ablated,  comprised only 13% of the 
number recovered from mice challenged with antigen only. 
1L-12  Prevents Airway  Hyperresponsiveness and  Pulmonary 
Eosinophilia Induced by Repeated Antigen  Challenge.  Because 
clinical asthma is characterized by chronic pulmonary inflam- Sham  ! 
Ag 
Ag + Isotype 
Ag + aIFN  T 
Ag + IL-12 
Ag + IL-12 + Isotype 
Ag + IL-12 + cdFN  T  I 
0  1~0  2~  " ~0  ~0  s~  ~0 
APTI (cm H20-s) 
Figure  5.  Dependence  of IL-12  ef- 
fects  on  IFN-"/.  Antigen-challenged 
mice were injected  with vehicle  or 1 p~g 
IL-12 i.p.  for 5 consecutive days begin- 
ning 2 d before challenge,  and measure- 
{w  ments were determined  3  d  after  chal- 
lenge.  Some  groups  were  injected  i.p.  I  [  with 2 mg isotype-matched  control m.Ab 
or anti-IFN-~/mAb -2 d and +1 d rel- 
ative  to  challenge.  Results  shown  are 
mean +  SE of  three to six mice per group. 
* P <0.05  compared with antigen-chal- 
lenged  non-IL-12-treated  groups  and 
IL-12  +  anti-lFN-~/-treated  group; 
compared  except antigen-  t0.05  with all 
￿9 0ho"  0.20" 050"  0.'40  0..'so "  0.60  only group; w  compared withall ex- 
cept  antigen  +  isotype and  antigen  + 
Eosinophils (10 5)  (xlFN-~/groups. 
marion, we examined whether IL-12 could suppress  these 
responses induced by repeated antigen challenge in our rou- 
tine model. 3 d after a second antigen challenge (10 d after 
the first challenge), airway responsiveness  to acetylcholine 
was significantly greater compared with that in mice given 
repeated sham challenges (Fig.  6).  The increase in airway 
responsiveness  observed after the second challenge tended 
to  be  greater than that observed  after the  first  challenge 
(Fig.  1).  IL-12 administration in sham-challenged mice (1 
p~g/d for 5 d)  reduced airway responsiveness,  but this re- 
duction did not reach significance.  In contrast, IL-12 ad- 
ministration at the time of a second antigen challenge re- 
sulted in  complete reduction of airway responsiveness  to 
control levels. 
Repeated  antigen  challenge  resulted  in  significant in- 
creases in all bronchoalveolar lavage cell types (Fig. 7), with 
eosinophils comprising 25-44% of all cells. IL-12 adminis- 
tration in sham-challenged mice caused significant increases 
in macrophages but not in other cell types. IL-12 adminis- 
tration in antigen-challenged mice significantly reduced all 
cell  types  except  macrophages.  Unlike  the  inflammatory 
response  observed after a single  challenge, IL-12 adminis- 
tration did not completely reduce eosinophil numbers to 
control levels,  although there was a  12-fold reduction in 
these cell numbers compared with vehicle-treated antigen- 
challenged mice. 
Discussion 
In this study, we demonstrate that airway hyperrespon- 
siveness  and pulmonary inflammation induced by antigen 
challenge are associated with a Th2 pattern ofcytokine ex- 
pression  in  the  murine  lung.  IL-12  administration  pre- 
vented the development of these responses  in conjunction 
with suppressing  the antigen-induced increases  in expres- 
sion of the Th2  cytokines IL-4 and IL-5.  Suppression of 
these two cytokines is particularly important because they 
have  been  implicated in  the  pathogenesis  of allergic  re- 
sponses  via  their role  in mediating IgE  production,  mast 
cell  activation,  and  eosinophilia.  Inhibition  of antigen- 
induced airway hyperresponsiveness by IL-12 was  depen- 
dent on IFN-~/  activity, but depletion of eosinophils was 
only partially IFN-~/  dependent.  IL-12 was  equally effec- 
tive  in  suppressing  airway hyperresponsiveness associated 
Sham 
Sham +  IL-12 
Ag 
Ag + 1L-12 
0  200  400  600  800  1000 
APTI  (cm H20-s) 
Figure 6.  Effect oflL-12 on airway responsiveness to i.v. acetylcholine 
(25 p,g/kg) in mice 3 d after a second intratracheal  challenge  with antigen 
or PBS  (sham).  Intratracheal challenge  was repeated 7  d  after  first  chal- 
lenge. Values shown are mean and SE of five to six mice per group. Sham- 
or antigen-challenged mice were treated with vehicle or I  ~g IL-12 for 5 
consecutive days beginning 2  d  before the second challenge.  *P <0.05 
compared with all other groups. 
3.0  f"l Sham 
*  []  Sham + IL-12 
￿9  Ag 
*  [~  Ag + IL-12 
2.0 
~  1.o 
0.0,  - 
Macrophages  Neutrophils  Lymphocytes  Eosinophils 
Figure  7.  Effect  of IL-12 on numbers of BAL inflammatory cells re- 
covered from mice 3 d after  a second antigen or sham challenge.  Values 
shown are mean and SE of five to six n~ce per group. Mice were chal- 
lenged and treated as described  in Fig. 6. *P <0.05 compared with sham 
group; ~Lp <0.05 compared with all other groups. 
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peated antigen challenge. These results support the concept 
that Th2  cytokines play a central role in antigen-induced 
allergic responses and provide the first in vivo evidence that 
IL-12 can suppress responses associated with allergic asthma. 
Antigen challenge induced increases  in pulmonary IL-4 
and IL-5 gene expression and protein levels, but not signif- 
icant increases  in IFN-%  concomitant with the develop- 
ment of antigen-induced airway hyperresponsiveness and 
pulmonary eosinophilia,  thus supporting a  role  for Th2- 
type cytokines in the development of these responses.  To 
our knowledge, this is the first demonstration of antigen- 
induced increases in cytokine proteins in murine BAL fluid. 
The  association  of antigen-induced airway hyperrespon- 
siveness and increased Th2-type cytokine expression is also 
consistent with our previous demonstration that these func- 
tional responses  are  dependent on CD4 + Th cells,  as ad- 
ministration  of a  monoclonal anti-CD4  antibody before 
antigen  challenge  completely  prevented  these  responses 
(21). Further support for a role for Th2 cytokines in these 
responses is the demonstration that BAL and bronchial mu- 
cosal T cells from allergic asthmatic patients produce higher 
levels of IL-4 and IL-5 than do cells from normal controls 
(11,  13-15).  Our results  are also consistent with previous 
reports examining cytokine expression in bronchial mucosa 
induced by allergen challenge (6). Several other lines of ev- 
idence indicate that IL-4 and IL-5 may play important im- 
munopathogenic  roles  in  the  development  of  allergic 
asthma. IL-4 has particularly been shown to be a primary 
determinant of Th2 cell differentiation (37) and is also es- 
sential for the production of IgE (17), which can mediate 
antigen-induced  mast  cell  degranulation.  Elevated  serum 
levels of IgE are characteristic  of allergic asthmatic individ- 
uals (11,  12), indicating a likely role for mast cell mediator 
release  as a significant component of allergen-induced air- 
way constriction. Mast cells release  a variety of preformed 
and newly synthesized mediators, which are potent bron- 
choconstrictors, in response to antigen stimulation (38). IL-4 
may also contribute to eosinophilia by promoting the up- 
regulation of endothelial vascular cell adhesion molecule-I, 
which controls the attachment and migration of eosinophils 
(39). IL-5 promotes the differentiation, recruitment, activa- 
tion, and survival of eosinophils (18-20, 40), which are con- 
sistendy elevated in blood and airways of allergic and nonal- 
lergic  asthmatic patients  compared  with  normal  subjects. 
Eosinophils may contribute to airway hyperresponsiveness 
by  releasing  mediators  that  induce  epithelial  injury  and 
bronchoconstriction, including major basic protein, leuko- 
trienes, and platelet-activating factor (41-43).  Our finding 
that expression of IL-5 mRNA was significantly increased 
in the lungs of antigen-challenged mice is consistent with 
the  elevation in  eosinophil numbers.  Other  studies  have 
also found increases in IL-5 levels after antigen challenge in 
animal models and human asthmatic individuals. For exam- 
ple, IL-5 induced in vitro airway hyperreactivity in guinea 
pigs,  whereas anti-IL-5 treatment completely inhibits this 
response  in  antigen-challenged  animals  (44). Anti-IL-5 
treatment also inhibits eosinophil recruitment into tracheal 
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submucosa of allergen-chaUenged mice (22). Other cyto- 
kines may also be important in the development of aller- 
gen-induced  airway  hyperresponsiveness,  including  IL-3 
(released by both Thl and Th2 cells) and IL-9, which con- 
tribute to the growth and activation of mast cells (16). 
IL-12 was  highly effective in preventing the  develop- 
ment of antigen-induced airway hyperresponsiveness and 
pulmonary inflammation in this murine model. The inhi- 
bition of pulmonary inflammation by IL-12 was most strik- 
ing with eosinophils, which have been proposed to mediate 
tissue injury and airway hyperresponsiveness (45, 46). Con- 
comitant with the prevention of these antigen-induced re- 
sponses,  IL-12 administration reduced antigen-induced in- 
creases in the levels of IL-4 and IL-5 protein and mRNA 
and increased the expression of the Thl  cytokine IFN-% 
giving further support for the concept that Th2 cytokines 
are  important  in  the  development  of allergic  responses. 
These results are consistent with the results of other studies 
of allergic models in which IL-12 suppresses Th2 cytokine 
expression and associated responses in vivo (31-33). 
In our study, IL-12 inhibition of antigen-induced airway 
hyperresponsiveness and eosinophilia was partially depen- 
dent on IFN-~/activity since coadministration ofanti-IFN-~/ 
mAb partially prevented these effects of IL-12. IFN-~/may 
mediate IL-12-induced suppression of antigen-induced air- 
way hyperresponsiveness and eosinophilia through its abil- 
ity to  inhibit  Th2  cytokines because  IL-12-induced  in- 
creases in IFN-~/protein levels were correlated with inhibition 
of Th2 cytokines. In addition, IFN-y may have direct ef- 
fects on effector cells such as eosinophils, B  cells, or mast 
cells.  The partial  dependence of antigen-induced eosino- 
philia  on  IFN-y  is  consistent with  studies  showing that 
IFN-  7  administration can block antigen-induced eosino- 
phil influx into murine airways (22,  47).  Because  IFN-y 
also  suppressed  antigen-induced  infiltration  of CD4 +  T 
cells in those studies,  its effects on CD4 + T  cells cannot be 
separated from any direct  effects it may have on  eosino- 
phils. The involvement oflFN-'y in IL-12 inhibition of an- 
tigen-induced airway hyperresponsiveness in  our study is 
also consistent with the ability of rlFN-~/ to reverse OVA- 
induced alterations in airway reactivity in mice (48). 
The lack of complete reversal  of IL-12 inhibition of al- 
lergic  responses  by  anti-IFN-~/  administration  may  also 
suggest that IL-12 directly suppresses  airway hyperrespon- 
siveness  and eosinophil production or stimulates produc- 
tion of mediators other than IFN-7 that have these effects. 
Alternatively, IL-12  could  directly inhibit  Th2  cytokine 
functions, such as inhibiting IL-4-mediated IgE production 
by an IFN-"/-independent mechanism, as demonstrated in 
vitro (30). In vivo, however, this effect can be at least par- 
tially IFN-~/  dependent because IFN-~/  mAb considerably 
inhibits IL-12 suppression  of IgE, mast cell, and eosinophil 
responses in worm-infected mice (32). The fact that airway 
hyperresponsiveness was  dose-dependendy suppressed  by 
IL-12, whereas Th2 cytokines and eosinophils were virtu- 
ally ablated at both doses, also supports the conclusion that 
IL-12 may directly inhibit effector cells such as mast cells 
and B  cells.  We  also  cannot rule  out the possibility that IL-12 or IL-12-induced IFN-~/may have direct effects on 
receptors  or  signal  transduction  mechanisms  in  airway 
smooth muscle that mediate airway responsiveness, because 
IL-12  tended  to  reduce  airway  responsiveness  in  sham- 
challenged  mice,  although  this  effect  was  not  statistically 
significant.  Alternatively,  the  lack  of complete  IFN-y de- 
pendence  of IL-12  effects  on  allergic  responses  may  be 
caused  by incomplete  anti-IFN-y neutralization  of IL-12- 
induced IFN-y, as has been suggested previously (31).  Fur- 
ther studies  with  mice that lack functional  IFN-'y (49)  or 
IFN-y receptor  gene  (50)  may be  needed  to  address  this 
question definitively. 
Novel therapeutic  approaches for the treatment of aller- 
gic  diseases  such  as  allergic  asthma  are  in  demand.  Such 
therapies  must be able to inhibit the chronic inflammation 
and  hyperresponsiveness  of asthmatic  individuals,  and  not 
merely prevent  acute  responses.  Strikingly,  administration 
of IL-12  concurrent  with  the  time  of a  second  antigen 
challenge completely inhibited the airway hyperresponsive- 
ness associated with repeated antigen exposure. Eosinophil 
numbers were reduced by 80% in IL-12-treated animals af- 
ter repeated antigen challenge compared with vehicle-treated 
challenged  mice,  and  other  inflammatory  cells  were  also 
significantly  reduced.  These  results  are  consistent  with 
those of a study in which IL-12 inhibited  established  Th2 
responses  in a murine  model of Schistosorna mansoni  infec- 
tion  (33).  In contrast,  IL-12 was ineffective in preventing 
Th2  responses,  with  the  exception  of eosinophilia,  after 
secondary infection with Nippostrongylus  brasiliensis (32), in- 
dicating that the ability of IL-12 to inhibit Th2-associated 
responses effectively may be dependent on type or level of 
antigen  exposure.  The ability  of IL-12 to prevent  in  vivo 
airway hyperresponsiveness associated with repeated antigen 
challenges strongly supports  the idea  that local administra- 
tion  of this  cytokine  or agents  that  induce  production  of 
this cytokine may be useful in the treatment of chronic al- 
lergic conditions such as atopic asthma. 
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